Zenas BioPharma Releases Q3 2025 Financial Results
Zenas BioPharma, Inc. (NASDAQ: ZBIO) has presented its financial results for the third quarter that concluded on September 30, 2025. The company, dedicated to transforming healthcare for patients with autoimmune diseases, has made noteworthy strides in its clinical programs and financial standing.
Significant Achievements in Clinical Trials
Lonnie Moulder, the founder and CEO of Zenas, emphasized the company's commitment to developing impactful treatments. Key highlights include:
- Phase 3 INDIGO Trial: The results for the obexelimab Phase 3 INDIGO trial focusing on Immunoglobulin G4-Related Disease (IgG4-RD) are anticipated towards the end of 2025.
- Successful Phase 2 Trial: Zenas reported excellent results from its Phase 2 MoonStone trial evaluating obexelimab in Relapsing Multiple Sclerosis (RMS), showcasing a remarkable reduction in lesions compared to the placebo.
- Expansion of Pipeline: The company has acquired development rights to three autoimmune product candidates, among them orelabrutinib, currently in Phase 3 for progressive forms of Multiple Sclerosis.
- Funding Milestones: A funding agreement with Royalty Pharma could provide up to $300 million to help support clinical development and eventual commercial launch plans.
Recent Corporate Highlights
Zenas's corporate activities are geared towards strengthening its position in the biopharmaceutical landscape:
- Pioneering IgG4-RD Research: The INDIGO trial is among the largest global studies dedicated to IgG4-RD, indicating Zenas's robust commitment towards understanding and treating this condition.
- Impressive Clinical Efficacy: The MoonStone trial revealed a 95% relative reduction in the cumulative number of gadolinium-enhancing lesions after 12 weeks. This suggests obexelimab could significantly advance RMS treatment.
- Innovative Licensing Agreements: Collaboration with InnoCare Pharma expands Zenas’s portfolio with orelabrutinib, alongside other promising drug candidates that target critical aspects of multiple sclerosis.
- Funding for Growth: The $120 million raised from a private placement will bolster Zenas's funding for ongoing research and development initiatives into 2026 and beyond.
Financial Overview
As of September 30, 2025, Zenas BioPharma reported cash and investments totaling $301.6 million. This amount is anticipated to sustain operations and capital requirements through 2026. The company recorded an R&D expense of $34.4 million for the quarter, reflecting its investment in advancing clinical trials, while G&A expenses soared to $13.2 million, primarily due to increased personnel costs and pre-commercialization expenses.
The net loss attributed to the common stockholders for Q3 2025 was $51.5 million, a rise from the $38.6 million recorded during the same period in 2024.
Pipeline Developments
Key updates regarding Zenas's pipeline include:
- Obexelimab: This candidate is undergoing trials for various autoimmune conditions. The company aims to complete enrollment for its Phase 2 SunStone trial, focusing on Systemic Lupus Erythematosus, by year-end 2025.
- Orelabrutinib: Preparing to embark on Phase 3 trials for both Primary and Secondary Progressive Multiple Sclerosis, marking a significant step forward in addressing these challenging forms of MS.
- Innovative Drug Candidates: Zenas is also progressing with ZB021 and ZB022, two advanced candidates that could offer groundbreaking treatment options for autoimmune conditions and neurologic diseases.
About Zenas BioPharma
Founded on the principles of providing transformative therapies to patients with autoimmune diseases, Zenas BioPharma is making considerable advancements in the field of biopharmaceuticals. With a strong leadership team and a disciplined approach to product acquisition, the company is focused on developing innovative therapies with the potential to significantly change patient lives.
Frequently Asked Questions
What recent results did Zenas BioPharma announce?
Zenas BioPharma announced positive financial results for Q3 2025 and significant progress in clinical trials for obexelimab and orelabrutinib.
What is obexelimab used for?
Obexelimab is a monoclonal antibody aimed at treating autoimmune diseases, including Relapsing Multiple Sclerosis and Immunoglobulin G4-Related Disease.
How is the company financially positioned?
Zenas reported $301.6 million in cash and investments, sufficient to fund operations through 2026 and beyond.
What are the next steps for Zenas's drug candidates?
Zenas plans to report Phase 3 trial results for obexelimab by the end of 2025 and is advancing orelabrutinib trials in 2026.
Where can I find more information about Zenas BioPharma?
You can visit Zenas BioPharma’s website for more information about their programs and updates.